Monday, October 16, 2017 10:02:12 AM
Lisak IS the MAN when it comes to MS..the Dr!
still reviewing time frame for first in mouse studies(how long they have taken in past..ran out of time this morning)
Quote:
238 - Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis
R.P. Lisak, L. Nedelkoska, J.A. Benjmains Neurology, Wayne State University School of Medicine, Detroit, MI, United States
Objectives: Determine if sigma-1 receptor (S-1R) agonists can provide protection for oligodendrocytes (OL), OL precursors (OPC) and central nervous system (CNS) neurons (Neu) and promote repair. Background: S-1R are endoplasmic reticulum (ER) chaperones upregulated during ER stress, and also regulate calcium homoeostasis via inositol triphosphate at the ER-mitochondrial interface. We reported that dextromethorphan (DM), a S-1R agonist and weak NMDA receptor (NMDAR) antagonist, protects OL and OPC from toxic effects of molecules important in the pathogenesis of multiple sclerosis (MS) and increases OPC proliferation. Other groups have found inhibition of an animal model of MS by DM and another S-1R agonist. We sought to examine the potential protective and reparative effects of ANAVEX2-73, also a S-1R agonist, an NMDAR antagonist and a weak muscarinic agonist, unrelated to DM, on OL, OPC and Neu and extend our studies of DM to Neu. For both ANAVEX2-73 and DM we investigated if protection was due to agonism of S-1R.
Methods: Cell cultures containing >90% OL, OPC or Neu were prepared from neonatal rats and were incubated with staurosporine (apoptosis), glutamate (excitotoxicity), H2O2 (reactive oxygen species; ROS), quinolinic acid (inflammation) or additional medium (control) with or without DM or ANAVEX2-73 (provided by ANAVEXTM Life Sciences Corp, under the SIGMACEPTOR (R) program). Neu cultures were incubated with the same toxic molecules with/without ANAVEX2-73 or DM. We incubated OPC with ANAVEX2-73 and evaluated proliferation as well as maturation.
Results: We found that ANAVEX2-73 inhibited death of OL, OPC and Neu induced by the toxic factors and confirmed that DM also protected Neu as well as OL and OPC. Pretreatment of cultures with S-1R antagonist BD1047 inhibited the protection provided by both ANAVEX2-73 and DM. As reported earlier for DM, ANAVEX2-73 increased OPC proliferation assessed by uptake of a uridinie analog (BrdU). ANAVEX2-73 differed from our published findings with DM as it also increased maturation of OPC to more mature OL based on expression of phenotypic markers.
Conclusions: ANAVEX2-73 and DM protect OL, OPC and Neu from several toxic molecules involved in pathogenesis of MS. Protection appears to be dependent on signaling through S-1R. Both ANAVEX2-73 and DM increase OPC proliferation. ANAVEX2-73 also accelerates OPC maturation to OL. S-1R agonists could provide both protection and help with repair in MS.
Disclosure:
Robert Lisak: Grant funding from Teva, Speakers List: Teva; Consulting: Teva, Syntimmune, Celgene and RedHill Biopharm.
Liljana Nedelkoska: Nothing to disclose
Joyce Benjamins: Nothing to disclose
Research funded by the Parker Webber Chair in Neurology, Wayne State University/DMC Foundation. ANAVEX2-73 supplied by ANAVEXTM Life Sciences Corp.
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM